Dupixent for chronic hives in NYC

The April 2026 US label includes adults and children age 2 or older with CSU that remains symptomatic despite H1 antihistamines. It is not approval for every type of hives. The dose depends on age and weight, and younger children do not use the adult loading regimen.

No. Dupixent is approved for CSU that remains symptomatic despite H1 antihistamines in adults and children age 2 or older. Other causes of hives need the appropriate diagnosis and treatment. The clinician reviews the pattern, duration, prior medicine and age-specific regimen before prescribing.

Confirm CSU and persistent symptoms despite H1 antihistamine treatment. The clinician reviews other diagnoses, age, weight and previous therapy. Physical-trigger hives and acute hives are not automatically included in this indication. The evaluation should define symptom goals before selecting treatment. Adults use a 600 mg loading dose followed by 300 mg every two weeks. Pediatric dosing depends on age and weight; ages 2–5 have no loading dose, while ages 6–17 use the label’s weight-based regimen. The prescriber must choose the actual order. A first appointment does not guarantee injection.

Adults use a 600 mg loading dose followed by 300 mg every two weeks. Pediatric dosing depends on age and weight; ages 2–5 have no loading dose, while ages 6–17 use the label’s weight-based regimen. The prescriber must choose the actual order. A first appointment does not guarantee injection.

Appropriate patients or caregivers may give Dupixent at home after training and clinician approval. The pen is labeled from age 2 and the syringe from age 6 months, but the approved age also depends on the condition. A caregiver administers it below age 12; those age 12 or older need adult supervision. Confirm the exact device and regimen.

Track hives, itch, swelling, sleep and other daily effects using a consistent method. Discuss response and adverse effects at the planned review; response is not guaranteed. Continue or adjust antihistamines through the treating clinician rather than assuming they stop with the first dose.

A consultation starts with the clinical review and required records. Treatment or a procedure depends on suitability, the actual order, safety checks, staff, supplies and any authorization; booking does not guarantee a dose or procedure that day. Adults use a 600 mg loading dose followed by 300 mg every two weeks. Pediatric dosing depends on age and weight; ages 2–5 have no loading dose, while ages 6–17 use the label’s weight-based regimen. The prescriber must choose the actual order. A first appointment does not guarantee injection.

No clinic or manufacturer can guarantee an insurer’s approval or payment. Confirm the exact clinic, product and appointment: evaluation, prescribing, training and administration are separate services. Bring an outside order before relying on administration at Nao. Drug, visit and administration benefits may be separate; manufacturer assistance does not guarantee insurance approval. Arrange the pharmacy, shipment and next review with the treating team. Local stock or same-day dosing is not established by approval.

Before treatment starts, confirm the diagnosis, the intended benefit, the exact treatment and who will coordinate ongoing care. Adults use a 600 mg loading dose followed by 300 mg every two weeks. Pediatric dosing depends on age and weight; ages 2–5 have no loading dose, while ages 6–17 use the label’s weight-based regimen. The prescriber must choose the actual order. A first appointment does not guarantee injection.

Prepare the relevant dated records, current medicine list and your main questions, and confirm any treatment-specific instructions before attending. Bring a symptom diary, photos, antihistamine names and doses, weight and prior treatment history. A caregiver administers treatment for children under 12; age 12 or older requires adult supervision. The clinician confirms the suitable device, training and home-treatment plan.

Agree on the next review, how response and safety will be checked, and who to contact for symptoms, missed treatment or a refill problem. Track hives, itch, swelling, sleep and other daily effects using a consistent method. Discuss response and adverse effects at the planned review; response is not guaranteed. Continue or adjust antihistamines through the treating clinician rather than assuming they stop with the first dose.

Bring a record of hives, itch, swelling, sleep disruption, dose dates and other medicines to the treating clinician. Persistent symptoms are a reason to reassess the diagnosis, treatment use, benefit and adverse effects. The clinician can discuss whether to continue or change the plan. Do not increase the dose, shorten the interval or combine advanced hives medicines on your own; the appropriate regimen depends on the exact product and clinical review.

Yes. Hives can occur as part of an allergic reaction to Dupixent, even though it is also prescribed for chronic spontaneous urticaria. New hives after a dose need prompt review. If you develop signs of an allergic reaction, stop using Dupixent and contact your healthcare provider or get emergency help right away. Breathing trouble, throat or facial swelling, or fainting needs emergency help. Do not assume a new reaction is simply your usual hives.